US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
アメリカ
USOTC
CD Projekt SA (PK) (OTGLF) 銘柄情報

CD Projekt SA (PK) (OTGLF)

59.25

0.00

(0.00%)

終了 7月11日 5:00AM

CD Projekt SA (PK) (OTGLF) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

59.25

( - )

買値

58.21

売値

65.13

出来高

-

平均取引量 (3 か月)

US$ 380,506

財務取引量

-

0.00 日の範囲 0.00

59.25 52 週間の範囲 75.93

時価総額

企業価値

22.341B

前日終値

59.25

始値

-

時刻

最終取引時間

VWAP

-

歳入

878.01M

純利益

589.11M

発行済株式数

99,822,596

浮動株比率 (%)

64.82%

機関投資家保有比率 (%)

37.22%

配当利回り

(0.45%)

PER

45.61

株価売上高倍率 (PSR)

26.52

1 株当たり利益 (EPS)

5.84

ベータ

0.4

CD Projekt S.A., together its subsidiaries, engages in the production, publishing, and digital distribution of video games and related products in Poland. The company’s flagship products include The Witcher series of games and Cyberpunk 2077. It also exports its products to Europe, North America, So... CD Projekt S.A., together its subsidiaries, engages in the production, publishing, and digital distribution of video games and related products in Poland. The company’s flagship products include The Witcher series of games and Cyberpunk 2077. It also exports its products to Europe, North America, South America, Asia, Australia, and Africa. The company was incorporated in 2001 and is headquartered in Warsaw, Poland. 詳細を表示

セクター

-

業界

-

ウェブサイト

www.cdprojekt.com

本社

Warsaw, Poland

設立

2026

CD Projekt SA (PK) is listed in the sector of the その他OTC with ticker OTGLF. The last closing price for CD Projekt (PK) was US$59.25. Over the last year, CD Projekt (PK) shares have traded in a share price range of US$ 59.25 to US$ 75.93.

CD Projekt (PK) currently has 99,822,596 shares in issue. The market capitalisation of CD Projekt (PK) is US$5.91 billion. CD Projekt (PK) has a price to earnings ratio (PE ratio) of 45.61.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	59.25	59.25	59.25	120	59.25	CS
12	-16.3278	-21.6039630685	75.5778	75.5778	59.25	33	60.50598462	CS
26	-9.75	-14.1304347826	69	75.93	59.25	77	70.79665455	CS
52	-10.8749	-15.5079009025	70.1249	75.93	59.25	94	68.98239063	CS
156	20.25	51.9230769231	39	77.5	24.6	245	45.54957236	CS
260	9.95	20.1825557809	49.3	77.5	13.05	460	40.48865408	CS

OTGLF - Frequently Asked Questions (FAQ)

What is the current CD Projekt SA (PK) share price?

The current share price of CD Projekt SA (PK) is US$ 59.25

How many CD Projekt SA (PK) shares are in issue?

CD Projekt SA (PK) has 99,822,596 shares in issue

What is the market cap of CD Projekt SA (PK)?

The market capitalisation of CD Projekt SA (PK) is USD 5.91B

What is the 1 year trading range for CD Projekt SA (PK) share price?

CD Projekt SA (PK) has traded in the range of US$ 59.25 to US$ 75.93 during the past year

What is the PE ratio of CD Projekt SA (PK)?

The price to earnings ratio of CD Projekt SA (PK) is 45.61

What is the cash to sales ratio of CD Projekt SA (PK)?

The cash to sales ratio of CD Projekt SA (PK) is 26.52

What is the registered address of CD Projekt SA (PK)?

The registered address for CD Projekt SA (PK) is Building E, Warsaw, 03-301

What is the CD Projekt SA (PK) website address?

The website address for CD Projekt SA (PK) is www.cdprojekt.com

BahamaPete

BahamaPete 4分前

Thanks OCKHAM's RAZOR, I added your links to my DD post. Go $TKOI

Helter Skelter

Helter Skelter 14分前

😆 "accurately captures one of the most critical underappreciated alliances..."

https://investorshub.advfn.com/uimage/uploads/2026/7/10/opnhmBB_Can_u_say_MONOPOLY_071026.png

🤑 $BB Where Nvidia Goes We Go $NVDA 🤑

Twiggs333

Twiggs333 20分前

CMPS Compass Pathways: A Structural Mispricing in Plain Sight?

Extremely good explanation of the value of this company by a Stanford Professor.

https://x.com/kevin__mak/status/2075541715272790373

Popeye

Popeye 21分前

Yeah, agreed. That was a shot of the dark guess of the discount for the Reg A and .08 would certainly move the numbers in the favor of the shareholder.
Unknowns are 1. What will the discount be and 2. How much will Korenko raise? (Doesn’t have to raise the entire $9 million now - maybe raise

Twiggs333

Twiggs333 22分前

Compass Pathways: A Structural Mispricing in Plain Sight?

https://x.com/kevin__mak/status/2075541715272790373

CA Market News

CA Market News 26分前

Lion One Announces Closing of Second Tranche of Non-Brokered Private Placement of Convertible Debenture Units and Units for Aggregate Gross Proceeds of $17.5 MillionJuly 10, 2026 11:14 PM
Newsfile

Genz2

Sorry, misspelled Greg’s last name in the previous post!!! It should be Kazmierczak!!

Gus1212

Gus1212 35分前

If this rejection theory is correct, I believe it was just a tactic to stall our approval process.
Sounds too simple, doesn't it!

Maybe paid for by you know who, big pharma.

They all know that DCVAX works; they are not dummies.
Why did they stall? Cou

Whalatane

Whalatane 46分前

A Fable 5 analysis
Synthesized FDA timeline risks, TDAPA reimbursement implications, and dilution concernsSynthesized FDA timeline risks, TDAPA reimbursement implications, and dilution concernsGood context to layer in.
Here's the deeper risk breakdown on those three fronts.

LTR

I think a suitable punishment for these guys would be to lock them up in ILT's vault and throw away the key.

Real McCoy

Real McCoy 52分前

Well yeah this one has the most lies.

3rd attempt: you ok with lies, yes or no?

pos_stock_hoarder

pos_stock_hoarder 53分前

New York Dolls - Looking for a Kiss

https://youtu.be/GvmvMFXWzc8

Genz2

https://techcrunch.com/2026/07/10/us-cyber-agency-cisa-had-to-build-its-incident-playbook-during-the-incident-agency-reveals/

According to Krebs, the researcher tried to alert the contractor but didn’t hear back. Only after Krebs contacted CISA did the agency take the repository offli

boston127

boston127 55分前

Hey,

Thanks for the links you sent me. My PC blocked all of the URLs due to malware protection. I'm still in GNIS and the other one. I was up but they have dive bombed quite rapidly. Now, in the RED. Both companies are interesting.

LTR

I have an idea AF may turn up in discovery when the dots are lined up and connected. AF may look to be a witness in order to avoid being a defendent.

conix

Non-promotional information until there is a press release is a wise move.

CatfishHunter

CatfishHunter 57分前

We should have news of next step well before years end. Vivos is already approved by FDA to start the EFS. Mayo Clinic needs to review and sign off on the approved conditions for the IRB and that’s just a formality. EFS could start as early as August. And 30 day patient status report about 45 days a

Philosophical Trader

Philosophical Trader 57分前

How is this doing? This was a great runner with a 2 year cup and handle.

nwtf

You really dont have a clue what you are talking about. Just stop.

rakp

rakp 1時間前

What do you think BB? Are there any official OTCMarkets notifications/filings and what's this CCLX price of .50 cents? This looks to good to be true.

Doc logic

Doc logic 1時間前

Galzus Research,

What if the end game is a friendly or two to the shorts were to bid for control at the lowest price possible before full Flaskworks validation or the value of Direct can be fully factored in by most investors while NWBO is still on the OTC? Just wondering. Best wish

ace65

ace65 1時間前

WOW...game changer!!Thanks for sharing

nwtf

nwtf 1時間前

LOL LOL LOL LOL

IOW they didnt offer the money they wanted.

CD Projekt (PK)

PT Media Nusantara Citra... (PK)

Motorola Solutions

Mel Invest Holding AD

Equity Idx Lkd Nts 30/03...

DJ Australia SmallCap

Life Insurance Company o... (ID)

Btp Tf 4,35% Nv33 Eur

CBD Life Sciences (ID)

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。